Platinib’s scope of application and mechanism of action

Pralsetinib is a drug targeting specific types of neuroendocrine tumors and lung cancer. It is mainly used to treat non-small cell lung cancer related to RET gene mutations. Platinib could provide a new treatment option for patients with this type of lung cancer, who often don't respond well to traditional chemotherapy or radiation. In particular, platinib has shown significant therapeutic effects for adult patients with locally advanced or metastatic RET gene fusion-positive NSCLC.

In thyroid cancer, RET gene mutation is also a common driver. Platinib is approved for the treatment of adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine. In addition, it is indicated for the treatment of adult and pediatric patients with advanced or metastatic RET mutated medullary thyroid cancer (MTC).

Platinib belongs to a class of drugs called "RET inhibitors". Its mechanism of action is mainly to inhibit the growth and spread of cancer cells by interfering with the abnormal signaling of RET receptors.

Platinib is a tyrosine kinase inhibitor that can inhibit specific kinases in tumor cells, such as METkinase and RETkinase. These kinases play key roles in several cancer types, including lung and thyroid cancers. By inhibiting these kinases, Platinib blocks tumor cell proliferation and spread.

Platinib has high selectivity forRET kinase, which means that it can act more accurately on target tumor cells and reduce toxic side effects on normal cells. Platinib is an oral once-daily medication, which offers patients convenience and better compliance.